Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2021
Novavax appoints an interim CFO
Novavax said Greg Covino would step down as CFO and become an executive adviser, while John Trizzino would assume the CFO role on an interim basis during a search for Covino's replacement.
2021
Novavax and SK Bioscience expand vaccine collaboration for South Korea
Novavax and SK Bioscience expanded their existing manufacturing arrangement for NVX-CoV2373. The agreement provides for technology transfer and adjuvant supply, while SK Bioscience finalized an advance purchase agreement with the Korean government to supply 40 million doses beginning in 2021.
2021
Novavax appoints Henrietta Ukwu as senior vice president
Novavax announced Henrietta Ukwu's appointment as Senior Vice President, Chief Regulatory and Quality Officer, in a newly created role.
2021
Singapore signs Novavax vaccine pre-purchase agreement
Singapore signed a pre-purchase agreement with Novavax in January 2021 to purchase its recombinant protein vaccine. Singapore hoped to receive the vaccine by the end of the year; it was still undergoing Phase 3 clinical trials and the government was awaiting the company’s application for approval.
2020
Novavax appoints Margaret G. McGlynn to its board
Novavax announced the appointment of Margaret G. McGlynn as an independent director to its board.
2020
Novavax expands manufacturing agreement with Serum Institute of India
Novavax announced an amendment to its existing agreement with Serum Institute of India under which the institute will also manufacture the antigen component of Novavax’s COVID-19 vaccine candidate NVX-CoV2373. Novavax said planned capacity would bring global manufacturing capacity to more than two billion doses annually by mid-2021.
2020
AGC Biologics expands Novavax partnership for U.S. adjuvant supply
AGC Biologics announced an expanded partnership with Novavax, adding production of the Matrix-M adjuvant for Novavax’s COVID-19 vaccine at AGC Biologics’ Seattle facility to support U.S. supply.
2020
Novavax appoints David Mott to its board
Novavax announced that it appointed David Mott as an independent director to its Board of Directors. Mott will serve on the board's Compensation Committee.
2020
CEPI announces additional funding for Novavax vaccine development
CEPI announced an investment of up to an additional $384 million to advance clinical development of Novavax's NVX-CoV2373 vaccine candidate, bringing CEPI's total investment in the candidate to $388 million.
2020
CEPI announces up to $384 million in additional funding for Novavax's COVID-19 vaccine development
CEPI announced an investment of up to an additional $384 million to advance clinical development of Novavax's NVX-CoV2373 vaccine candidate; the stated total CEPI investment in the candidate would reach $388 million.
2020
Emergent BioSolutions and Novavax partner on coronavirus vaccine development
Emergent BioSolutions is working with Novavax to develop a coronavirus vaccine; under the agreement, Emergent will produce an experimental vaccine based on Novavax's formula.
2019
Novavax reports third-quarter 2019 results
Novavax announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2019, reporting a third-quarter net loss of $18.0 million.
2019
Catalent completes purchase of Novavax manufacturing assets
Novavax and Catalent Biologics closed a transaction under which Catalent purchased Novavax manufacturing equipment and related assets for approximately $18 million, assumed leases to two facilities, and hired approximately 100 manufacturing and quality employees.